CGEN
Price
$1.64
Change
-$0.07 (-4.09%)
Updated
Nov 4 closing price
7 days until earnings call
ORMP
Price
$2.39
Change
+$0.01 (+0.42%)
Updated
Nov 4 closing price
3 days until earnings call
Ad is loading...

CGEN vs ORMP

Header iconCGEN vs ORMP Comparison
Open Charts CGEN vs ORMPBanner chart's image
Compugen
Price$1.64
Change-$0.07 (-4.09%)
Volume$153.05K
CapitalizationN/A
Oramed Pharmaceuticals
Price$2.39
Change+$0.01 (+0.42%)
Volume$92.34K
CapitalizationN/A
View a ticker or compare two or three
CGEN vs ORMP Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CGEN vs. ORMP commentary
Nov 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a StrongBuy and ORMP is a StrongSell.

COMPARISON
Comparison
Nov 05, 2024
Stock price -- (CGEN: $1.64 vs. ORMP: $2.38)
Brand notoriety: CGEN and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 74% vs. ORMP: 105%
Market capitalization -- CGEN: $147.4M vs. ORMP: $97.23M
CGEN [@Biotechnology] is valued at $147.4M. ORMP’s [@Biotechnology] market capitalization is $97.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $498.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • CGEN’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, CGEN is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • CGEN’s TA Score: 4 bullish, 3 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CGEN is a better buy in the short-term than ORMP.

Price Growth

CGEN (@Biotechnology) experienced а -2.96% price change this week, while ORMP (@Biotechnology) price change was +2.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.74%. For the same industry, the average monthly price growth was +10.27%, and the average quarterly price growth was +7.68%.

Reported Earning Dates

CGEN is expected to report earnings on Feb 20, 2025.

ORMP is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-1.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($147M) has a higher market cap than ORMP($97.2M). ORMP YTD gains are higher at: 3.247 vs. CGEN (-17.172). ORMP has higher annual earnings (EBITDA): 25.5M vs. CGEN (-4.55M). ORMP has more cash in the bank: 153M vs. CGEN (92M). ORMP has less debt than CGEN: ORMP (486K) vs CGEN (3.03M). CGEN has higher revenues than ORMP: CGEN (42.7M) vs ORMP (0).
CGENORMPCGEN / ORMP
Capitalization147M97.2M151%
EBITDA-4.55M25.5M-18%
Gain YTD-17.1723.247-529%
P/E RatioN/A4.68-
Revenue42.7M0-
Total Cash92M153M60%
Total Debt3.03M486K623%
FUNDAMENTALS RATINGS
CGEN vs ORMP: Fundamental Ratings
CGEN
ORMP
OUTLOOK RATING
1..100
5669
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9354
PRICE GROWTH RATING
1..100
4850
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CGEN's Valuation (37) in the Biotechnology industry is in the same range as ORMP (53) in the Pharmaceuticals Other industry. This means that CGEN’s stock grew similarly to ORMP’s over the last 12 months.

CGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that CGEN’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for CGEN (93) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than CGEN’s over the last 12 months.

CGEN's Price Growth Rating (48) in the Biotechnology industry is in the same range as ORMP (50) in the Pharmaceuticals Other industry. This means that CGEN’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (99) in the Pharmaceuticals Other industry is in the same range as CGEN (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENORMP
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDSCX38.750.16
+0.41%
Fidelity Stock Selector Small Cap
HTMIX10.86N/A
+0.03%
Heitman US Real Estate Secs Instl
GUBGX15.61N/A
N/A
Victory RS International A
GIIZX12.19N/A
N/A
GuideStone Funds Intl Eq Idx Investor
FTZFX50.67-0.13
-0.26%
FullerThaler Behvrll Uncnstd Eq R6